Perturbomics: CRISPR–Cas screening-based functional genomics approach for drug target discovery
Authors:
Open Access
- 1 July 2025
- journal article
- review article
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 57 (7) , 1443-1454
Abstract
Despite more than two decades since the completion of the first draft of the Human Genome Project, a substantial proportion of human genes remain poorly characterized in terms of their functions. Functional genomics aims to elucidate the roles and interactions of genes and genetic elements, providing insights into their involvement in various biological processes. In this context, the perturbomics approach—a systematic analysis of phenotypic changes resulting from gene function modulation—offers valuable insights into the function of unannotated genes. With the advent of CRISPR–Cas-based genome and epigenome editing, CRISPR screens have become the method of choice for perturbomics studies, enabling the identification of target genes whose modulation may hold therapeutic potential for diseases such as cancer, cardiovascular disorders and neurodegeneration. These findings contribute to the development of targeted drug therapies and the design of gene and cell therapies for regenerative medicine. Here we highlight recent technical advances in CRISPR-based perturbomics, focusing on more physiologically relevant, single-cell-level analyses and their successful applications in discovering novel therapeutic strategies.Keywords
Funding Information
- National Research Council of Science and Technology (CAP23011-000)
- Korea Institute of Science and Technology (2E33131)
- National Research Foundation of Korea (RS-2024-00452719)
This publication has 105 references indexed in Scilit:
- Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormonesCell, 2023
- CAR-T Therapies in Solid Tumors: Opportunities and ChallengesCurrent Oncology Reports, 2023
- In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy targetCell, 2021
- In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8+ T cell fate decisionsCell, 2021
- Acquired Resistance to Immune Checkpoint InhibitorsCancer Cell, 2020
- Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T CellsCell, 2019
- Darkness in the Human Gene and Protein Function Space: Widely Modest or Absent Illumination by the Life Science Literature and the Trend for Fewer Protein Function Discoveries Since 2000Proteomics, 2018
- Defining a Cancer Dependency MapCell, 2017
- Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic ScreensCell, 2016
- Dissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-SeqCell, 2016